Compare CCG & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCG | BYSI |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 35.8M |
| IPO Year | 2023 | 2016 |
| Metric | CCG | BYSI |
|---|---|---|
| Price | $17.11 | $0.72 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $350.00 | N/A |
| AVG Volume (30 Days) | 19.7K | ★ 1.9M |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $567.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.67 |
| 52 Week High | $17.99 | $2.44 |
| Indicator | CCG | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 67.30 | 33.47 |
| Support Level | $0.65 | N/A |
| Resistance Level | N/A | $1.30 |
| Average True Range (ATR) | 1.86 | 0.12 |
| MACD | -0.27 | 0.00 |
| Stochastic Oscillator | 70.38 | 11.04 |
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services, and other services in China. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.